Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 30:11:707214.
doi: 10.3389/fonc.2021.707214. eCollection 2021.

Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions

Iris Tung  1 , Arvind Sahu  1
Affiliations
Review

Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions

Iris Tung et al. Front Oncol. .

Abstract

The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the last decade with multi-targeted tyrosine kinase inhibitors (TKI) previously used as first-line treatment but its utility is limited by short-lived efficacy and rapid disease progression. The dysregulation of immune cells in the tumour microenvironment contributes to unregulated growth of RCC. Thus, the use of immune checkpoint inhibitors has become first-line treatment for metastatic RCC and has offered dramatic improvement in clinical benefit and survival. Treatment with immune checkpoint inhibitor in combination with TKI appears to be promising in offering even greater response rates. The treatment for metastatic RCC continues to evolve and ongoing advances with new targeted agents and biomarkers are needed to continue to improve prognosis in the future.

Keywords: anti-VEGF (vascular endothelial growth factor) agents; biomarker; immune checkpoint inhibition (ICI); metastatic renal carcinoma; tyrosine kinase inhibitions (TKIs) therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline of FDA-approved treatment for metastatic RCC in first-line setting.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. 10.3322/caac.21493 - DOI - PubMed
    1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. . Epidemiology of Renal Cell Carcinoma. World J Oncol; (2020) 11(3):79–87. 10.14740/wjon1279 - DOI - PMC - PubMed
    1. Ljungberg B, Campbell S, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. . The Epidemiology of Renal Cell Carcinoma. Eur Urol (2011) 60(4):615–21. 10.1016/j.eururo.2011.06.049 - DOI - PubMed
    1. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. . Renal Cell Carcinoma. Nat Rev Dis Primers (2017) 3:17009. 10.1038/nrdp.2017.9 - DOI - PMC - PubMed
    1. Heng DY, Xie W, Regan MM, Warren M, Golshayan AR, Sahi C, et al. . Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. J Clin Oncol (2009) 27(34):5794–9. 10.1200/JCO.2008.21.4809 - DOI - PubMed

LinkOut - more resources